Brief: Citius Pharmaceuticals Announces Closing Of Registered Direct Offering Of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
12/06/2025 13:52
June 12 (Reuters) - Citius Pharmaceuticals Inc CTXR.O: CITIUS PHARMACEUTICALS ANNOUNCES CLOSING OF REGISTERED DIRECT OFFERING OF UP TO $15.8 MILLION PRICED AT-THE-MARKET UNDER NASDAQ RULES Source text: ID:nPn5n7vPsa Further company coverage: CTXR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules